We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Charcoal tablets in the treatment of patients with irritable bowel syndrome.
- Authors
Hübner, Wolf D; Moser, Ewald H
- Abstract
This double-blind, randomized, multicenter, prospective clinical trial evaluated a commercial formulation of charcoal tablets (Eucarbon) and tablets containing only nonactivated charcoal (carbo ligni [CL]) in 284 patients between the ages of 19 and 70 years with irritable bowel syndrome (IBS). After 12 weeks, 262 patients were available for intention-to-treat analysis. Overall well-being, the primary efficacy parameter, was determined by means of the Francis scoring system. Eucarbon treatment alleviated symptoms by about 60%, but the relative gain in efficacy vis-à-vis the CL group was only 9%. Several clinical observations and subgroup analyses, however (eg, in patients suffering from constipation), showed that Eucarbon was more effective. Both treatments were well tolerated and produced adverse events at a similar frequency (22%, Eucarbon vs 17%, CL). In most cases, it was not possible to distinguish the adverse event from symptoms of IBS. The herbal preparation Eucarbon was effective and safe in IBS, a complex disease requiring long-term treatment.
- Publication
Advances in therapy, 2002, Vol 19, Issue 5, p245
- ISSN
0741-238X
- Publication type
Journal Article
- DOI
10.1007/BF02850364